echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Treatment form of severe head and neck cancer ushered in immunotherapy, its five-year survival rate is about to be refreshed

    Treatment form of severe head and neck cancer ushered in immunotherapy, its five-year survival rate is about to be refreshed

    • Last Update: 2021-01-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The latest statistics show that cancer deaths account for 23.91% of all deaths in China, and cancer has become one of the major public health problems that seriously threaten the health of residents.
    the 13th Five-Year Plan period, the Health China Initiative was launched, with cancer prevention and treatment as an important component, and the goal of curbing the trend of cancer morbidity and death and improving the overall five-year survival rate of cancer was also proposed.
    with the joint efforts of all parties, cancer prevention and treatment has entered a period of precise breakthrough, the need to pay attention to the past neglected high incidence of cancer, such as head and neck cancer.
    At a recent roundtable discussion on the media of head and neck cancer, Professor Guo Wei of the China Society of Clinical Oncology (CSCO), Professor Guo Wei of Shanghai Oriental Hospital, Professor Yang Kunxuan, Director of the Oncology Department of Concord Hospital of Hua zhong University of Science and Technology, and Professor Han Fei, Deputy Director of Radiotherapy Department of Sun Yat-sen University Cancer Prevention and Control Center, gathered to share the current status of head and neck cancer disease and treatment.
    The ninth-highest incidence rate in the country has long been neglected, according to the latest data from the International Agency for Research on Cancer, the number of new cases of head and neck cancer in China reached 142,000 in 2020, second only to the eighth-highest incidence of thyroid cancer, with nearly 75,000 deaths, showing a steady upward trend.
    there are still many people who lack understanding of head and neck cancer and have long ignored this type of high incidence of cancer.
    China Clinical Oncology Society (CSCO) Head and Neck Cancer Committee, Professor Guo Wei of Shanghai Oriental Hospital, "Head and neck cancer can be divided into oral cancer, throat cancer, nasopharyngeal cancer according to the site of several categories, different parts of the symptoms will be different."
    "Oral cancer often manifests it as a long-lasting mouth ulcer or a lump in the mouth, including ulcers or new organisms at the root of the tongue or tongue, and patients with throat cancer may experience hoarseness or difficulty swallowing, " says Professor Guo.
    " head and neck cancer has a great relationship with living habits.
    If the examination found that the oral mucosa or vocal band white spots and pyrethroid changes, may be head and neck cancer precancer lesions, need follow-up and timely stop bad habits.
    of people with head and neck cancer have a habit of smoking and drinking alcohol, tobacco and alcohol are undoubtedly the main carcinogens.
    addition, residents in Taiwan or parts of Hunan have a habit of chewing betel nut.
    and penang contains the carcinogenic factor published by the World Health Organization (WHO) - penang base, leading to a high incidence of local oral cancer.
    the United States, the incidence of related pharynx cancer due to HPV infection is increasing year by year.
    this end, in June 2020, the U.S. Food and Drug Administration (FDA) approved a nine-price HPV vaccine to prevent oral and neck cancer and other head and neck cancers caused by some HPV types, making it possible to prevent some head and neck cancer.
    Immunotherapy refreshes the long survival record of advanced head and neck cancer precisely because many people do not understand head and neck cancer, ignoring the possible pre-cancer lesions, 70% to 80% of patients diagnosed with head and neck cancer is already local late or late stage, need comprehensive treatment and more prone to recurrence.
    -related data show that the mortality rate of patients with head and neck cancer is high, and the five-year survival rate of relapsed or metastatic head and neck cancer is only 3.6%. Professor Yang Kunxuan, director of the oncology department of Concord Hospital of Huahua University of Science and Technology, lamented: "Head and neck cancer is in a very special position, treatment may affect the patient's organ function and appearance, so consideration needs to be more comprehensive."
    treatment of head and neck cancer is more limited in the past, the biggest breakthrough in recent years is that head and neck cancer has a first-line immunotherapy.
    ", in December 2020, Paboli-Pearl monoantigen was approved by China's State Drug Administration (NMPA) for the evaluation of tumor expression PD-L1 (comprehensive positive score (C) through a fully validated test PS) ≥20) metastatic or non-removable reoccessive head and neck squamous cell carcinoma (HNSCC) patients first-line treatment, is the first specific late-stage head and neck squamous cancer patients first-line immunotherapy.
    latest data from
    show that in some patients with head and neck cancer, Paboli juju monotherapy compared to the standard treatment of sytoxides monotherapy, the four-year survival rate was 21.6% and 8%, almost three times that of the standard treatment group.
    Relative chemotherapy, immunotherapy is more safe, its mechanism of operation is to mobilize autoimmune cells to attack tumor cells, and use its immune memory function to keep the patient's tumor in a state of long-term withdrawal, so that some patients to achieve long-term survival, close to "cure."
    more and more studies have moved immunotherapy forward, hoping to verify that it has better therapeutic effects at different stages of tumor development, in order to further improve the cure rate and reduce the recurrence rate.
    despite the outstanding efficacy, many patients are still looking for immunotherapy for financial burden reasons.
    In order to reach more patients, from 2021 onwards, the Patient Assistance Program, sponsored by Merca East and sponsored by the China Primary Health Care Foundation, has been fully adapted: on first application, patients are required to use a two-course Pabliju single-dose injection, as directed by the doctor, and are reviewed by the Foundation After passing, it can be assisted with 2 courses of treatment, follow-up application, the patient followed the doctor's instructions to use 2 courses of Paboliju monoantigen injection, the Foundation can continue to assist them until the progression of the disease, but the cumulative use of Paboliju monoantigen injection amount of patients does not exceed 24 months.
    " latest patient assistance programme as a whole has fallen to about a quarter of what it used to be, significantly reducing the financial burden on patients.
    who are less financially well-off can also apply to join clinical trials and be provided with the opportunity to use Pabliju monoanti.
    " Professor Guo Wei called, "I would like to say to all patients with relapsed head and neck cancer, we must believe in the value of immunotherapy, but also believe in our professional team of doctors."
    nearly three times as much long-term survival benefits as possible by participating in immunotherapy on a case-by-case basis.
    " to build a new ecology of head and neck cancer, multidisciplinary diagnosis and treatment is the key Zhongshan University Cancer Prevention and Control Center radiotherapy department deputy director Professor Han Fei because of the location of the disease is critical, the treatment of head and neck cancer needs to work together between different departments, medically known as multidisciplinary diagnosis and treatment model (MDT).
    " head and neck cancer has been dominated by surgery and radiotherapy, with the emergence of chemotherapy, targeted treatment and immunotherapy, the participation of physicians is increasing, and even imaging, pathology, nuclear medicine and nutrition doctors.
    " Professor Han Fei added, "The multidisciplinary approach is not just patient treatment, it involves patient rehabilitation training after treatment and toxic side effects management."
    departments should be based on the patient's situation, according to the conditions of the disease, timely according to the patient's situation reasonable choice of treatment options and arrangements for treatment order, to better ensure the maximum benefit of patients.
    " In order to focus on the construction of China's head and neck cancer discipline treatment, in 2018 CSCO head and neck tumor special committee was established, and formulated the CSCO head and neck tumor diagnosis and treatment guide, to help improve the level of primary diagnosis and treatment of head and neck cancer.
    addition to updating and revising the guidelines, in 2021, we will conduct nationwide tours to promote awareness of immunologic drugs and the management of related toxic side effects.
    " Professor Guo said, "We also hope to use the association's continuing education function, so that the group of doctors engaged in the diagnosis and treatment of head and neck tumors in-depth understanding of immunotherapy, with this treatment weapon."
    " Professor Guo Wei is confident about the future of head and neck cancer in China.
    He believes that with the CSCO head and neck cancer task force work continues to advance, multidisciplinary diagnosis and treatment model and standardized immunotherapy has been further popularized, clinical research continues to explore the possibility of immunotherapy jointly expand more beneficiaries, the future of China's head and neck cancer diagnosis and treatment will enter a new stage.
    source: Medical Valley.com Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Originals" on this website are owned by Mets Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.